710. Optimization of AAV Vector Design for Safe Expression of β-N-Acetylhexosaminidase in the Brain for Tay-Sachs Disease Gene Therapy
Diane Golebiowski(University of Massachusetts Chan Medical School), Miguel Sena‐Esteves(University of Massachusetts Chan Medical School), Wael F. Asaad(Allen Institute for Brain Science), Rosemary Santos(University of Massachusetts Chan Medical School), Keiko Y. Petrosky(New England Biolabs (United States)), Douglas R. Martin(Auburn University), Julie G. Pilitsis(University of Arizona), Kajo van der Marel(University of Massachusetts Chan Medical School), Elizabeth Hutto(Harvard University), Nina Bishop(University of Massachusetts Chan Medical School), Elizabeth Curran(New England Biolabs (United States)), Matthew J. Gounis(University of Massachusetts Chan Medical School), Sheila Cummings Macri(Harvard University), Elena Balkanska-Sinclair(University of Massachusetts Chan Medical School)
Cited by 0
Related Papers
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
|Nature Communications|2018|328
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain
|Neuroscience|2006|200
The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma
|Cancer Cell|2011|156
Requirement of the ATM/p53 Tumor Suppressor Pathway for Glucose Homeostasis
|Molecular and Cellular Biology|2010|118
Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation
|Journal of Lipid Research|2018|109